Search results
Results from the WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
Drug delivery to the brain is the process of passing therapeutically active molecules across the blood–brain barrier into the brain.This is a complex process that must take into account the complex anatomy of the brain as well as the restrictions imposed by the special junctions of the blood–brain barrier.
Neuroplasticity is the process by which neurons adapt to a disturbance over time, and most often occurs in response to repeated exposure to stimuli. [27] Aerobic exercise increases the production of neurotrophic factors [note 1] (e.g., BDNF, IGF-1, VEGF) which mediate improvements in cognitive functions and various forms of memory by promoting blood vessel formation in the brain, adult ...
"The brain communicates via electrical signaling, and technologies like deep brain stimulation therapy help us interface with the brain circuitry to improve and/or restore more normal connectivity ...
In this podcast episode, Medical News Today shares three actionable resolutions that can help improve brain, heart, and metabolic health in the new year via diet, sleep, and exercise. Brain health ...
“In the brain of an adult living with depression, something has gone awry with the plasticity and the protection of the neuronal population,” says McIntyre.
2008: Sanofi Pasteur acquires Acambis plc, a biotech company. 2009: Sanofi Pasteur acquires major stake in Hyderabad-based Shantha Biotechnics. [21] 2020: Sanofi Pasteur and GlaxoSmithKline have said they are starting clinical trials of their coronavirus vaccine. They hope to have the first results of the trial by December and if it is ...
Sanofi quoted Houman Ashrafian, its head of research and development, as saying that it "represents an unprecedented breakthrough as a potential first-in-disease treatment option with clinically ...